We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

By LabMedica International staff writers
Posted on 30 May 2023
Print article
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with the United States witnessing more deaths from lung cancer than from colon, prostate, and breast cancers combined. Although immune checkpoint inhibitors (ICIs) are commonly used in the treatment of lung cancer, their effectiveness is compromised by low response rates, high costs, and the risk of therapy-induced side effects.

Scientists at Calviri, Inc. (Phoenix, AZ, USA) studying the efficacy of ICI therapies in patients with advanced lung cancer have discovered that anti-frameshift peptide antibodies (anti-FSP antibodies), a new category of blood-based biomarkers, have the potential to be developed into improved or new orthogonal tests for predicting tumor responses to treatment. Interestingly, these antibodies could also be instrumental in predicting immune-related adverse events (irAEs) in patients with lung cancer. As part of their investigation, the scientists evaluated serum samples taken from 74 advanced lung cancer patients prior to their treatment with anti-PD-L1 or anti-PD-1 immunotherapy, with or without concurrent chemotherapy. The presence of antibodies recognizing FSPs was detected on peptide microchips. These biomarkers successfully predicted post-treatment tumor responses and adverse events with a remarkable 90-100% accuracy, using a single test.

Despite its small scale, this study signifies the first significant step towards reliably predicting immunotherapy outcomes, potentially leading to improved patient outcomes. Simple, accurate tests to forecast therapy outcomes could empower doctors to suggest treatments for patients who are most likely to benefit, including those with cancers typically resistant to ICIs. Such a predictive test would also enable the identification of patients requiring close monitoring for potential toxicities, allowing therapy doses to be adjusted or paused if necessary. It might also affect the decision to combine chemotherapy with primary ICI therapy for certain patients, as chemotherapy does not always provide additional benefits over ICIs. Predicting whether it is needed could alter treatment recommendations. Furthermore, the implications of this research extend beyond lung cancer, suggesting that for other cancers like brain cancer—where ICIs have traditionally shown low response rates—a screening test for responsive patients could be a lifesaver.

"In previous studies, other biomarkers have shown some encouraging results for predicting ICI therapy tumor responses. However, extraction and testing are elaborate, often unreliable, and sometimes not possible, and there is no test for predicting adverse events," said Kathryn Sykes, the Vice President of Research and Product Development at Calviri. "Our study explores anti-FSP antibodies as novel biomarkers, which can be simply and accurately measured from a small amount of blood."

"We expect these results will justify the approach and facilitate access to the required larger serum sample cohorts for developing and licensing predictive diagnostics based on this technology," said Stephen Albert Johnston, CEO of Calviri. "Future efforts will focus on improving this approach for addressing specific needs in lung cancer treatment and for evaluating this ICI predictive test platform for other research."

Related Links:
Calviri, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.